Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.55 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.45 |
| ▸ | CDC25A | P30304 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20769675 | 0.82 | AKR1C3 (0.72) | AKR1C3AKR1C2ABCB1PTGS1AKR1C4 | |
| SCHEMBL13802421 | 0.80 | KMT2A (0.57) | AKR1C3AKR1C2ABCB1PTGS1AKR1C4 | |
| SCHEMBL13802399 | 0.80 | KMT2A (0.59) | ALDH1A1KMT2APTGS2POLB | |
| SCHEMBL9153676 | 0.80 | AKR1C3 (0.50) | AKR1C3AKR1C2ABCB1PTGS1AKR1C4 | |
| SCHEMBL27474952 | 0.80 | AKR1C3 (0.59) | AKR1C3AKR1C2ABCB1PTGS1AKR1C4 | |
| SCHEMBL2467334 | 0.78 | CDC25A (0.54) | AKR1C3AKR1C2ALDH1A1LMNAMCL1 | |
| SCHEMBL16476520 | 0.76 | AKR1C3 (0.55) | AKR1C3AKR1C2ABCB1PTGS1AKR1C4 | |
| SCHEMBL31432746 | 0.76 | CDC25A (0.55) | ALDH1A1LMNAMCL1CDC25APOLB | |
| SCHEMBL12479702 | 0.76 | CDC25A (0.51) | ALDH1A1LMNAMCL1CDC25APLK1 | |
| SCHEMBL13813994 | 0.76 | PTGS2 (0.54) | ALDH1A1KMT2APTGS2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | AKR1C3 570/4885AKR1C2 653/4885ABCB1 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.